Andrew Do

Also affiliated with San Jose State University

MedicineBiochemistry, Genetics and Molecular BiologyPharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers”.

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100187

N/A

0DataRank · unranked

33 citations

Jaime L. Schneider, Tejas Patil, Viola W. Zhu, Debra A. Goldman, Soo-Ryum Yang +13 more

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.07.16.452681

N/A

0DataRank · unranked

2 citations

Ted W. Johnson, Ibiayi Dagogo‐Jack, Mari Mino–Kenudson, Theodore R. Johnson, Ping Wei +16 more

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100534

N/A

0DataRank · unranked

13 citations

Lesli A. Kiedrowski, Rebecca S. Heist, W. Marston Linehan, Catherine B. Meador, Elizabeth Krueger +7 more

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution

npj Precision Oncology(2023)10.1038/s41698-023-00464-y

N/A

0DataRank · unranked

8 citations

Khvaramze Shaverdashvili, Mari Mino–Kenudson, Subba R. Digumarthy, Andrew Do, Audrey Liu +5 more

Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib

JCO Oncology Practice(2023)10.1200/op.23.00031

N/A

0DataRank · unranked

7 citations

Amanda Manoogian, Nicholas A. Jessop, N. Zeke Georgantas, Florian J. Fintelmann, Alexander Farahani +17 more

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100645

N/A

0DataRank · unranked

4 citations

Jiyoon Kang, Beow Y. Yeap, Jennifer Peterson, Andrew Do, Justin F. Gainor +3 more

GUK1 activation is a metabolic liability in lung cancer

Cell(2025)10.1016/j.cell.2025.01.024

N/A

0DataRank · unranked

16 citations

Kiran Kurmi, Yutong Dai, Ishita Dhiman, Shakchhi Joshi, Brandon M. Gassaway +21 more